Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness

European Journal of Cancer

Volumn 42, Issue 8, 2006, Pages 1057-1061

  Tagliabue, Elda ^a   Agresti, Roberto ^a   Casalini, Patrizia ^a   Mariani, Luigi ^a   Carcangiu, Maria Luisa ^a   Balsari, Andrea ^b   Veronesi, Umberto ^c   Ménard, Sylvie ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer; HER2; Surgery

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST SURGERY; CANCER INVASION; CANCER SURGERY; CANCER SURVIVAL; CONSERVATIVE TREATMENT; CONTROLLED STUDY; FEMALE; HAZARD ASSESSMENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MORTALITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; RETROSPECTIVE STUDY; SEGMENTAL MASTECTOMY; SURGICAL TECHNIQUE; TUMOR;

ADULT; BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODE EXCISION; MASTECTOMY, RADICAL; MIDDLE AGED; NEOPLASM INVASIVENESS; ONCOGENE PROTEINS V-ERBB; SURVIVAL ANALYSIS;

EID: 33646431425     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.12.021     Document Type: Article

References (14)

1. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.C., Keith D.E., et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
2. Ménard S., Balsari A., Casalini P., Tagliabue E., Campiglio M., Bufalino R., et al. HER2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 8 (2002) 520-525
3. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
4. Van'T Veer L.J., Dai H., Van de Vijver M.J., He Y.D., Hart A.A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
5. Press M.F., Bernstein L., Thomas P.A., Meisner L.F., Zhou J.Y., Ma Y.L., et al. HER2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15 (1997) 2894-2904
6. Cooke T., Reeves J., Lannigan A., Stanton P., et al. The value of the human epidermal growsth factor receptor-2 (HER2) as a prognostic marker. Eur J Cancer 37 (2001) 3-10
7. Volpi A., De Paola F., Nanni O., Granato A.M., Bajorko P., Becciolini A., et al. Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. Breast Cancer Res Treat 63 (2000) 181-192
8. Ross J.S., Muraca P.J., and Jaffe D. Multivariate analysis of prognostic factors in lymph node negative breast cancer. Mod Pathol 11 (1998) 26a
9. Tagliabue E., Agresti R., Carcangiu M.L., Ghirelli C., Morelli D., Campiglio M., et al. Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 362 (2003) 527-533
10. Veronesi U., Saccozzi R., Del Vecchio M., Banfi A., Clemente C., De Lena M., et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. New Engl J Med 305 (1981) 6-11
11. Grambsch P., and Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81 (1994) 515-526
12. Heimann R., and Hellman S. Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J Clin Oncol 18 (2000) 591-599
13. Birner P., Oberhuber G., Stani J., Reithofer C., Samonigg H., Hausmaninger H., et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER2 protein expression in breast cancer. Clin Cancer Res 7 (2001) 1669-1675
14. Colleoni M., Gelber S., Coates A.S., Castiglione-Gertsch M., Gelber R.D., Price K., et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol 19 (2001) 4141-4149